This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
Pooled safety analyses have not shown a clear excess of pancreatitis for this class, and the background rate in the population being treated is already elevated by obesity, gallstones and alcohol. That said, the labels carry the warning, and the presentation is distinctive enough to act on: severe persistent upper-abdominal pain radiating to the back, usually with vomiting, not relieved by anything.
Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.
So the question, as narrowly as I can put it: what the pooled safety data actually shows for this class, as opposed to what the label warning implies. Not looking for reassurance. Looking for the part I have got wrong.
Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.